Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of elismetrep, compared with placebo, for treating moderate to severe migraine in adults. This randomized, double-blind, multicenter outpatient study focuses on patients aged 18 to 75 who experience frequent migraine attacks. The trial aims to better understand elismetreps impact on migraine symptoms and relief. Participants are randomly assigned to receive a single oral dose of either elismetrep 10 mg, elismetrep 20 mg, or placebo. The study is conducted in a parallel design with triple masking to reduce bias. The primary focus is on pain freedom and relief from the most bothersome migraine symptoms within two hours after dosing. During the trial, participants will report their migraine symptoms and responses to treatment using study questionnaires and an electronic diary. Researchers will assess outcomes such as pain relief at 2 hours, sustained pain freedom up to 48 hours, freedom from nausea, photophobia, and phonophobia, and the need for rescue medication. Safety is monitored through adverse event reporting up to 8 days post-dose. The study is expected to last until December 2027.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal conjugate vaccine called PG4 in adults aged 18 to 49 years. The study compares three different production lots of the PG4 vaccine to each other and to an existing 20-valent pneumococcal conjugate vaccine 20vPnC to confirm consistent vaccine performance and safety. Participants are randomly assigned to one of four groups three groups receive one of the three different lots of the PG4 vaccine, and the fourth group receives the 20vPnC vaccine. Each participant receives a single injection of their assigned vaccine in the arm. The study uses a randomized, double-blind design with groups allocated in a 2221 ratio to ensure balanced comparison. During the approximately six-month study participation, blood samples are collected to measure immune responses and monitor safety. Researchers assess local and systemic reactions within one week after vaccination, adverse events up to one month, and serious adverse events up to six months. They also analyze specific antibody levels and immune activity to evaluate how the vaccines stimulate the bodys defenses against pneumococcal disease.
Actively Recruiting
The trial investigates the long-term safety of avacopan in adults diagnosed with antineutrophil cytoplasmic antibody ANCA-associated vasculitis, a condition requiring immunosuppressive treatment. This phase 4, randomized, double-blind, placebo-controlled study aims to assess treatment-emergent adverse events and other safety markers over a period of up to 5 years. Participants include those newly diagnosed or experiencing a relapse of granulomatosis with polyangiitis or microscopic polyangiitis, with specific antibody and disease activity criteria. Participants are randomly assigned to one of three groups avacopan 30 mg twice daily for 5 years with standard immunosuppressive therapy, avacopan 30 mg twice daily for 1 year followed by placebo for 4 years with standard therapy, or placebo twice daily for 5 years with standard therapy. All participants receive background immunosuppressive care as determined by their doctors. Treatments are administered orally, and the study maintains double-blinding to compare safety and efficacy outcomes across groups. Throughout the study, participants undergo regular safety assessments including vital signs, blood tests, serum chemistry, and urine analysis to monitor any significant changes from baseline. Researchers evaluate adverse events, remission status, kidney function, health survey scores, and glucocorticoid or immunosuppressant use over the 5-year period. The study includes continuous monitoring for serious adverse events, treatment withdrawals, and deaths related to the intervention, ensuring detailed long-term safety data collection.
Actively Recruiting
Healthy Volunteer
Researchers are studying the effectiveness, safety, and tolerability of a vaccine against Clostridioides difficile C. difficile infection in adults aged 65 years and older. The study aims to reduce the number of C. difficile infections, a serious cause of diarrhea, by comparing the vaccine to a placebo. This is a phase 3, randomized, double-blinded trial sponsored by Pfizer. Participants will receive either the C. difficile vaccine or a saline placebo, both given as shots into the upper arm muscle. The study duration varies based on the occurrence of diarrhea events related to C. difficile infection, lasting up to about three and a half years. The study may end earlier if sufficient data is collected or if the vaccine is found ineffective. Vaccination involves two doses, and participants will be closely monitored during and after vaccination. During the study, participants will have three planned clinic visits and three phone visits, followed by annual clinic visits until the study ends. If participants have three or more loose stools in 24 hours, they must save the next stool and contact the study site for infection assessment, which can occur in person or remotely. Researchers will track local and systemic reactions, adverse events, and the incidence of C. difficile infections as primary outcomes over the study period.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
This research aims to evaluate the rate of malposition and related clinical outcomes of the Hydrus Microstent implant in patients with primary open-angle glaucoma undergoing cataract surgery. The study focuses on patients with age-related cataracts and glaucoma managed with up to four topical medications, assessing device placement and safety over a 24-month period after surgery. Participants will undergo cataract surgery with placement of a monofocal intraocular lens followed immediately by implantation of the Hydrus Microstent device. The Hydrus Microstent is a crescent-shaped implant designed to create a pathway for fluid drainage in the eye. The study is a single-group, non-randomized clinical trial where all participants receive this combined treatment. During the study, participants will attend a screening visit, the surgery day, and eight post-operative visits scheduled from Day 1 through Month 24 to monitor device position and associated clinical effects. Researchers will track adverse events during surgery and post-operation and measure the rate of significant device malposition linked to clinical outcomes. The study is sponsored by Alcon Research and lasts up to 24 months post-surgery.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
1-10 of 18
1